Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX1 | P07099 | 1/20 | 0.53 |
| ▸ | ALPI | P09923 | 1/20 | 0.48 |
| ▸ | PKM | P14618 | 1/20 | 0.48 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.48 |
| ▸ | XIAP | P98170 | 1/20 | 0.48 |
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.48 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.47 |
| ▸ | POLB | P06746 | 2/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.45 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.45 |
| ▸ | SRR | Q9GZT4 | 2/20 | 0.44 |
| ▸ | SLC1A3 | P43003 | 1/20 | 0.44 |
| ▸ | SLC1A2 | P43004 | 1/20 | 0.44 |
| ▸ | SLC1A1 | P43005 | 1/20 | 0.44 |
| ▸ | NPC1 | O15118 | 1/20 | 0.44 |
| ▸ | RAB9A | P51151 | 1/20 | 0.44 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.44 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.44 |
| ▸ | TAAR1 | Q96RJ0 | 2/20 | 0.44 |
| ▸ | MAOA | P21397 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14591098 | 1.00 | EPHX1 (0.53) | EPHX1ALPIPKMPTGS1XIAP | |
| SCHEMBL15426321 | 0.85 | CYP1A2 (0.55) | ALPIPKMPTGS1XIAPSLC7A5 | |
| SCHEMBL66965 | 0.85 | CYP1A2 (0.55) | ALPIPKMPTGS1XIAPSLC7A5 | |
| SCHEMBL5608948 | 0.84 | SLC7A5 (0.49) | EPHX1SLC7A5SLC6A2TAAR1 | |
| SCHEMBL19787829 | 0.83 | TRPA1 (0.45) | EPHX1ALPIPKMPTGS1XIAP | |
| SCHEMBL20363221 | 0.83 | ALPI (0.50) | ALPIPKMPTGS1XIAPSLC7A5 | |
| SCHEMBL12650596 | 0.83 | ALPI (0.50) | ALPIPKMPTGS1XIAPSLC7A5 | |
| SCHEMBL5139885 | 0.82 | EPHX1 (0.38) | EPHX1ALPIPKMPTGS1XIAP | |
| SCHEMBL3944545 | 0.82 | EPHX1 (0.46) | EPHX1ALPIPKMPTGS1XIAP | |
| SCHEMBL9692685 | 0.81 | CYP1A2 (0.47) | ALPIPKMPTGS1XIAPSLC7A5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11786605-B2 | Site specific antibody-drug conjugates with peptide-containing linkers | MERSANA THERAPEUTICS, INC. (US) | 2023-10-17 | — | — | US | disclosed |
| US-20230183326-A1 | PROTEIN-POLYMER-DRUG CONJUGATES | ASANA BIOSCIENCES, LLC | 2023-06-15 | — | — | US | disclosed |
| US-20230183326-A1 | PROTEIN-POLYMER-DRUG CONJUGATES | ASANA BIOSCIENCES, LLC | 2023-06-15 | — | — | US | disclosed |
| US-20230043447-A1 | PEPTIDE-CONTAINING LINKERS FOR ANTIBODY-DRUG CONJUGATES | MERSANA THERAPEUTICS, INC. | 2023-02-09 | — | — | US | disclosed |
| US-20210220477-A1 | SITE SPECIFIC ANTIBODY-DRUG CONJUGATES WITH PEPTIDE-CONTAINING LINKERS | MERSANA THERAPEUTICS, INC. | 2021-07-22 | — | — | US | disclosed |
| US-10603386-B2 | Protein-polymer-drug conjugates | MERSANA THERAPEUTICS, INC. (US) | 2020-03-31 | — | — | US | disclosed |
| US-20190241649-A1 | PROTEIN-POLYMER-DRUG CONJUGATES | MERSANA THERAPEUTICS, INC. | 2019-08-08 | — | — | US | disclosed |
| US-20180154018-A1 | PEPTIDE-CONTAINING LINKERS FOR ANTIBODY-DRUG CONJUGATES | MERSANA THERAPEUTICS, INC. | 2018-06-07 | — | — | US | disclosed |
| US-9872918-B2 | Hydroxyl-polymer-drug-protein conjugates | MERSANA THERAPEUTICS, INC. (US) | 2018-01-23 | — | — | US | disclosed |
| US-20170348424-A1 | PROTEIN-POLYMER-DRUG CONJUGATES | MERSANA THERAPEUTICS, INC. | 2017-12-07 | — | — | US | disclosed |
| US-20160067353-A1 | PROTEIN-POLYMER-DRUG CONJUGATES | MERSANA THERAPEUTICS, INC. | 2016-03-10 | — | — | US | disclosed |
| US-20150366982-A1 | PROTEIN-POLYMER-DRUG CONJUGATES AND METHODS OF USING SAME | MERSANA THERAPEUTICS, INC. | 2015-12-24 | — | — | US | disclosed |
| US-20150306240-A1 | HYDROXYL-POLYMER-DRUG-PROTEIN CONJUGATES | MERSANA THERAPEUTICS, INC. | 2015-10-29 | — | — | US | disclosed |
| US-9144615-B2 | Protein-polymer-drug conjugates | MERSANA THERAPEUTICS, INC. (US) | 2015-09-29 | — | — | US | disclosed |
| US-20150125474-A1 | PROTEIN-POLYMER-DRUG CONJUGATES | MERSANA THERAPEUTICS, INC. | 2015-05-07 | — | — | US | disclosed |
| US-20150104407-A1 | PROTEIN-POLYMER-DRUG CONJUGATES | MERSANA THERAPEUTICS, INC. | 2015-04-16 | — | — | US | disclosed |
| US-20150044160-A1 | PROTEIN-POLYMER-DRUG CONJUGATES | MERSANA THERAPEUTICS, INC. | 2015-02-12 | — | — | US | disclosed |
| US-8821850-B2 | Protein-polymer-drug conjugates | MERSANA THERAPEUTICS, INC. (US) | 2014-09-02 | — | — | US | disclosed |
| US-20140134127-A1 | Protein-Polymer-Drug Conjugates | MERSANA THERAPEUTICS, INC. (US) | 2014-05-15 | — | — | US | disclosed |
| US-20140017265-A1 | Terminally Modified Polymers and Conjugates Thereof | MERSANA THERAPEUTICS, INC. | 2014-01-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (16 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150104407-A1 | PROTEIN-POLYMER-DRUG CONJUGATES | PBRM1, STAMBP, TSPO | EPHX1 4344/4885ALPI 2630/4885PKM 51/4885 |
| US-20150044160-A1 | PROTEIN-POLYMER-DRUG CONJUGATES | PBRM1, CLTB, BRAP | EPHX1 4311/4885ALPI 3267/4885PKM 141/4885 |
| US-20190241649-A1 | PROTEIN-POLYMER-DRUG CONJUGATES | PBRM1, STAMBP, TSPO | EPHX1 4344/4885ALPI 2630/4885PKM 51/4885 |
| US-20150366982-A1 | PROTEIN-POLYMER-DRUG CONJUGATES AND METHODS OF USING SAME | PBRM1, BCR, ERBB2 | EPHX1 4590/4885ALPI 3704/4885PKM 167/4885 |
| US-20170348424-A1 | PROTEIN-POLYMER-DRUG CONJUGATES | PBRM1, CLTB, BRAP | EPHX1 4311/4885ALPI 3267/4885PKM 141/4885 |
| US-20140134127-A1 | Protein-Polymer-Drug Conjugates | PBRM1, CLTB, BRAP | EPHX1 4311/4885ALPI 3267/4885PKM 141/4885 |
| US-20230183326-A1 | PROTEIN-POLYMER-DRUG CONJUGATES | PBRM1, STAMBP, TSPO | EPHX1 4344/4885ALPI 2630/4885PKM 51/4885 |
| US-20140017265-A1 | Terminally Modified Polymers and Conjugates Thereof | MALT1, ALG1, PRMT3 | EPHX1 3806/4885ALPI 3643/4885PKM 1882/4885 |
| US-20230043447-A1 | PEPTIDE-CONTAINING LINKERS FOR ANTIBODY-DRUG CONJUGATES | CD2BP2, DNPEP, LNPEP | EPHX1 3270/4885ALPI 3890/4885PKM 3804/4885 |
| US-20160067353-A1 | PROTEIN-POLYMER-DRUG CONJUGATES | PBRM1, CLTB, BRAP | EPHX1 4311/4885ALPI 3267/4885PKM 141/4885 |
| US-20150306240-A1 | HYDROXYL-POLYMER-DRUG-PROTEIN CONJUGATES | PBRM1, HDGFL3, CLTB | EPHX1 3465/4885ALPI 3582/4885PKM 82/4885 |
| US-11786605-B2 | Site specific antibody-drug conjugates with peptide-containing linkers | CD2BP2, DNPEP, LNPEP | EPHX1 2454/4885ALPI 3499/4885PKM 4112/4885 |
| US-20150125474-A1 | PROTEIN-POLYMER-DRUG CONJUGATES | PBRM1, STAMBP, TSPO | EPHX1 4344/4885ALPI 2630/4885PKM 51/4885 |
| US-10603386-B2 | Protein-polymer-drug conjugates | PBRM1, CLTB, BRAP | EPHX1 4460/4885ALPI 3648/4885PKM 86/4885 |
| US-20210220477-A1 | SITE SPECIFIC ANTIBODY-DRUG CONJUGATES WITH PEPTIDE-CONTAINING LINKERS | CD2BP2, DNPEP, LNPEP | EPHX1 2454/4885ALPI 3499/4885PKM 4112/4885 |
| US-20180154018-A1 | PEPTIDE-CONTAINING LINKERS FOR ANTIBODY-DRUG CONJUGATES | CD2BP2, DNPEP, LNPEP | EPHX1 3270/4885ALPI 3890/4885PKM 3804/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.